Streetbeat News

Earnings

META

Meta Platforms, Inc. (formerly known as Facebook) reported that its Average Daily Users (ADUs) have increased to 2.11 billion, marking a 6% year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:07 pm

TEAM

Atlassian (NASDAQ:TEAM) reported Q2 adjusted EPS of $0.73, surpassing the $0.62 estimate, marking a 62.22% year-over-year increase. Sales reached $1.06B, exceeding the $1.02B estimate, up 21.46% from the previous year.

Portfolio Pulse from totan@benzinga.com

February 01, 2024 | 9:07 pm

META

Meta Platforms reported Q4 2023 earnings of $5.33 per share, surpassing the $4.95 estimate, with sales of $40.11B exceeding the $39.17B forecast. This represents a 24.70% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:06 pm

SXI

Standex International (NYSE:SXI) reported Q2 earnings with an EPS of $1.78, beating estimates by 3.49% but with a revenue decrease of $9.39 million from the previous year. Past quarters show a pattern of beating EPS estimates but mixed revenue results.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:05 pm

CLFD

Clearfield (NASDAQ:CLFD) reported Q1 earnings with an EPS of $-0.35, beating estimates by 18.6% but with a revenue decrease of $51.71 million from the previous year. The company has a history of surpassing EPS estimates, which previously led to a share price increase.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:05 pm

SXI

Standex International (NYSE:SXI) reported Q2 adjusted EPS of $1.78, surpassing the $1.72 estimate, marking a 2.3% year-over-year increase. However, its sales of $178.40M fell short of the $182.52M estimate, a 5% decrease from the previous year.

Portfolio Pulse from totan@benzinga.com

February 01, 2024 | 9:04 pm

NRIX

Nurix Therapeutics announced the publication of research in the journal Science, revealing that BTK mutations, even those lacking kinase activity, are susceptible to degradation by their clinical stage BTK and IKZF1/3 degrader, NX-2127. This finding is significant for treating chronic lymphocytic leukemia and other B-cell malignancies. Positive clinical data from an ongoing Phase 1 trial of NX-2127 was also presented at the 65th American Society of Hematology Annual Meeting, showing therapeutic benefits in patients with relapsed/refractory B-cell malignancies.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:04 pm

AMZN

Amazon reported a year-over-year sales increase across its segments: North American sales grew by 12%, International sales by 11%, and AWS (Amazon Web Services) sales by 13%.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:03 pm

AMZN

Amazon has projected its operating income for Q1 2024 to be between $8 billion and $12 billion.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:02 pm

HOLX

Hologic, Inc. (NASDAQ:HOLX) reported Q1 adjusted earnings of $0.98 per share, surpassing the consensus estimate of $0.95, a 3.16% beat. However, this represents an 8.41% decrease from last year's earnings of $1.07 per share. The company's quarterly sales reached $1.01 billion, exceeding the consensus estimate of $986.12 million by 2.73%, yet marking a 5.68% decrease from the previous year's $1.07 billion.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:02 pm